Clinical Trial Update: Anagre Cap. in Patients With High-Risk Essential Thrombocythemia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for Anagre Cap. in high-risk essential thrombocythemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• Anagre Cap.

Snippet

Sponsor: Yuhan Corporation | Conditions: Essential Thrombocythemia | Phase 4 | Status: COMPLETED